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Abstract 
Background: While sub‑microscopic malarial infections are frequent and potentially deleterious during pregnancy, 
routine molecular detection is still not feasible. This study aimed to assess the performance of a Histidine Rich Protein 
2 (HRP2)‑based ultrasensitive rapid diagnostic test (uRDT, Alere Malaria Ag Pf ) for the detection of infections of low 
parasite density in pregnant women.
Methods: This was a retrospective study based on samples collected in Benin from 2014 to 2017. A total of 942 
whole blood samples collected in 327 women in the 1st and 3rd trimesters and at delivery were tested by uRDT, 
conventional RDT (cRDT, SD BIOLINE Malaria Ag Pf ), microscopy, quantitative polymerase chain‑reaction (qPCR) and 
Luminex‑based suspension array technology targeting P. falciparum HRP2. The performance of each RDT was evalu‑
ated using qPCR as reference standard. The association between infections detected by uRDT, but not by cRDT, with 
poor maternal and birth outcomes was assessed using multivariate regression models.
Results: The overall positivity rate detected by cRDT, uRDT, and qPCR was 11.6% (109/942), 16.2% (153/942) and 
18.3% (172/942), respectively. Out of 172 qPCR‑positive samples, 68 were uRDT‑negative. uRDT had a significantly 
better sensitivity (60.5% [52.7–67.8]) than cRDT (44.2% [36.6–51.9]) and a marginally decreased specificity (93.6% 
[91.7–95.3] versus 95.7% [94.0–97.0]). The gain in sensitivity was particularly high (33%) and statistically significant in 
the 1st trimester. Only 28 (41%) out of the 68 samples which were qPCR‑positive, but uRDT‑negative had detectable 
but very low levels of HRP2 (191 ng/mL). Infections that were detected by uRDT but not by cRDT were associated with 
a 3.4‑times (95%CI 1.29–9.19) increased risk of anaemia during pregnancy.
Conclusions: This study demonstrates the higher performance of uRDT, as compared to cRDTs, to detect low para‑
site density P. falciparum infections during pregnancy, particularly in the 1st trimester. uRDT allowed the detection of 
infections associated with maternal anaemia.
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Background
In sub-Saharan Africa (SSA), around 39 million pregnant 
women are exposed to malaria every year [1]. Malaria in 
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the leading causes of maternal anaemia, low birthweight 
and fetal growth restriction, which are high risk factors 
for neonatal and infant morbidity and mortality [1, 2].
Several studies have evidenced high proportions of 
sub-microscopic infections—that are not detectable by 
microscopy because of low parasite densities—among 
pregnant women [3]. In Benin, this proportion was as 
high as 25% at the first antenatal care visit in early first-
trimester [4]. Besides, these infections have been asso-
ciated with a reduction in birth weight, as well as an 
increase in low birth weight and maternal anaemia [3, 
5, 6], especially those occurring early in pregnancy or 
in primigravidae [3]. Although intermittent preventive 
treatment (IPTp) with sulfadoxine-pyrimethamine (SP) 
could theoretically clear and reduce the prevalence of 
such infections during pregnancy [3], resistance of para-
sites to SP and the low IPTp coverage in most SSA coun-
tries [1] are factors that limit its effectiveness. Besides, 
the administration of IPTp-SP is only recommended from 
the second trimester onwards. The accurate identification 
and treatment of women with sub-microscopic infections 
in the first trimester of pregnancy may be of high clinical 
relevance considering the high prevalence and significant 
deleterious effects of these early infections [7–9].
Sub-microscopic infections can be detected by nucleic 
acid amplification techniques (such as Polymerase Chain 
Reaction (PCR) or Loop-mediated isothermal Amplifi-
cation), however these require highly trained staff, rela-
tively sophisticated laboratory infrastructure and cannot 
be used in a point-of-care (POC) manner for malaria. 
Malaria rapid diagnostic test (RDT) are useful POC tool 
to screen pregnant women for malaria. Recently, a His-
tidine Rich Protein 2 (HRP2)-based ultrasensitive rapid 
diagnostic test (uRDT) has been made available (Alere 
Malaria Ag Pf ultra-sensitive RDT), with an analytical 
sensitivity (i.e. a detection threshold) ten times higher 
than conventional RDTs [10]. This test showed good per-
formances compared to PCR in pregnant women in low 
transmission malaria areas [11, 12].
This study aimed to assess the performance of this 
uRDT, compared to conventional RDT (cRDT) and 
qPCR, for the detection of P. falciparum malaria in 
peripheral and placenta blood from pregnant women in 
Benin, a high malaria-endemic area. Also, the association 
of uRDT-positive/cRDT-negative infections with poor 
maternal and birth outcomes was assessed.
Methods
Study site and population
This retrospective study was performed using blood 
samples collected during the RECIPAL study conducted 
in Southern Benin (2014–2017) [13]. Briefly, RECIPAL 
aimed to assess the prevalence and consequences of 
malaria in the first trimester of pregnancy on maternal 
and child health. It was based on a cohort of 411 preg-
nant women who were recruited before conception and 
then followed monthly from early pregnancy to deliv-
ery. In April 2018, 378 out of the 411 pregnant women 
(92%) consented to have the samples collected during 
the RECIPAL study used for the present study. Among 
the remaining women, 20 had migrated to Nigeria, 9 
refused to participate, 2 were lost to follow-up and 2 were 
deceased.
Sample collection and handling
During the RECIPAL study, each month during preg-
nancy, EDTA preserved capillary blood samples were col-
lected to detect malaria parasites using microscopy. At 
the same occasions, 50µL of whole blood was blotted on 
filter paper to make dried blood spot, which were dried, 
preserved at −20  °C and used for DNA extraction. The 
different types and volumes of blood that were used for 
microscopy, qPCR, RDTs and HRP2 level determination 
are presented in Additional file 1.
In addition, EDTA preserved venous blood samples 
were collected twice during pregnancy (at 1st and 3rd tri-
mester, for haemoglobin determination), as well as twice 
at delivery (one sample from maternal peripheral blood 
and one sample from placental blood), from which 500µL 
of whole blood was stored in −20 °C freezers. Those fro-
zen samples were used for RDT testing, consisting in one 
to four samples per woman depending on whether she 
completed the study follow-up until delivery.
Women with uncomplicated microscopic malaria were 
treated immediately with oral quinine in the 1st trimes-
ter and artemether-lumefantrine in the 2nd and 3rd 
trimesters. Those with severe malaria received intrave-
nous artesunate until oral medication could be tolerated. 
Women received a long-lasting insecticide-treated net 
at their first ANC visit. Besides, the maternity staff was 
encouraged to administer at least three doses of IPTp as 
recommended by national guidelines [13].
RDT and uRDT testing
The cRDT SD BIOLINE Malaria Ag Pf (05FK50, batch 
05CDD019AA, Abbott USA) and the HRP2 ultra-
sensitive RDT Alere Malaria Ag Pf (05FK140, batch 
05LDD001AA, Abbott USA) were used according to 
the manufacturer’s instructions. Each RDT reaction was 
performed in duplicate using 5 µL of previously frozen 
EDTA-anticoagulated venous whole blood and read in a 
blind manner. For each RDT reaction, the result of each 
test line was quantitatively recorded by two independ-
ent readers on a scale from 0 (no line) to 4 (strong line) 
using a standardized scoring chart. A P. falciparum posi-
tive blood sample was used as positive control to have a 
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positive example of scales before RDTs testing. Therefore, 
a total of 4 readings were performed with each product 
for a given specimen. A specimen was considered RDT 
positive if at least one reader identified one repeat as pos-
itive (i.e. test line intensity > 0) and negative if all readings 
were negative (i.e. test line intensity = 0).
Microscopy and qPCR testing
Microscopy and quantitative PCR (qPCR) testing was 
performed in the framework of RECIPAL study. Thick 
blood smears (TBS) were stained with Giemsa and para-
sitaemia was quantified by the Lambaréné method [14]. 
Blood smears were considered negative if no parasites 
were seen in all the 10µL TBS. The presence of P. falci-
parum was also tested in duplicate by a qPCR that tar-
geted the 18S rDNA after 40 cycles of amplification [15, 
16]. Starting from 50 µL of blood spotted on filter paper, 
the extraction procedure leads to a final volume of 150 µL 
extracted DNA. A test sampling of 5 µL extracted DNA 
thus corresponds to approximately 1.7 µL of blood. All 
parasite density estimates for this study were determined 
by qPCR. Parasitaemia was determined by extrapolation 
of cycle thresholds (Ct) from a standard curve gener-
ated with purified DNA from 3D7 P. falciparum infected 
erythrocyte culture. Samples without amplification (no 
cycle thresholds detected) were considered negative, 
and a density of 2 parasites/μL was assigned if amplifica-
tion was observed out of the lower range of the standard 
curve (5 parasites/μL). Purified DNA 3D7 parasite strain 
was used as a positive control while negative control with 
no DNA template was run in all reactions. Plasmodium 
falciparum infections detected by qPCR, but not by 
microscopy, were classified as sub-microscopic. A quality 
check qPCR (using FTD Malaria, FastTrack Diagnostics) 
was performed in Hôpital Bichat (France) on same DNA 
extracts from a 10% randomly selected sub-sample. This 
reagent is for detection of Plasmodium spp. DNA. The 
limit of detection was estimated by the manufacturer of 
0.1 target copy/µl of DNA extract. Considering that the 
PCR was carried out using 10 μL of DNA extract (equiv-
alent to 3.4  μl of whole blood), the detection limit was 
equivalent to 0.3 parasites/μl of whole blood. If the sam-
ple displayed an exponential trace under cycle threshold 
38, this sample was considered as positive.
Plasmodium falciparum HRP2 quantification
HRP2 was quantified using a highly sensitive laboratory 
based quantitative bead suspension array (qSA) based on 
Luminex technology [17]. After incubating 2’000 mag-
netic beads per analyte with blood sample at 1:5 dilution, 
beads were sequentially incubated with in-house bioti-
nylated antibody α-HRP2 (MBS832975, MyBiSource, 
San Diego, CL) and streptavidin-PE (42250-1ML, Sigma 
Aldrich, St. Louis, MO). After a final wash, a minimum 
of 50 microspheres per analyte were acquired using the 
Luminex  xMAP® 100/200 analyser (Luminex Corp., Aus-
tin, TX). After subtracting background (blank) values, 
median fluorescent intensities (MFI) were normalized to 
account for plate to plate variation and quantification was 
performed against a 5-parameter logistic (5-PL) regres-
sion curve consisting of recombinant protein HRP2 type 
A (890015, Microcoat GmbH, Germany).
Statistical analysis
For both RDTs, Kappa coefficients were estimated to 
assess agreement among the different readings. The posi-
tivity rate by diagnostic test (qPCR, uRDT, cRDT and 
microscopy) as well as the proportion of sub-microscopic 
infections were calculated. The sensitivity, specificity, 
positive predictive value (PPV), negative predictive value 
(NPV), positive likelihood ratio (LR +) and negative like-
lihood ratio (LR-) of each RDT were assessed compared 
to qPCR considered as reference standard. Secondary 
analyses were performed to assess RDTs’ performance 
according to gravidity (primi- and secundigravidae vs. 
multigravidae), trimester of pregnancy (1st trimester, 3rd 
trimester, and delivery), type of blood sample (peripheral 
vs. placental blood at delivery), and symptoms (sympto-
matic vs. asymptomatic women). Symptomatic women 
were those who presented fever (axillary tempera-
ture ≥ 37.5  °C) or history of fever in the preceding 24 h, 
whether malaria infection was detected by qPCR, uRDT 
or cRDT. For each sub-group, sensitivity and specificity 
were compared between uRDT and cRDT using McNe-
mar test for matched pairs. For all performance char-
acteristics, exact binomial confidence intervals were 
computed. The geometric mean (95% Confidence Inter-
val) of parasite density and HRP2 concentration were 
presented according to qPCR and RDT positivity.
The clinical impact of infections detected by the uRDT 
and not the cRDT was assessed. For that purpose, at each 
time-point of malaria screening using uRDT (i.e., at the 
1st trimester, at the 3rd trimester and at delivery), women 
were categorized in four exclusive groups as detailed in 
Table 1. Groups 3 and 4 included both qPCR positive and 
qPCR negative specimens in order to assess the impact of 
uRDT and cRDT infections in a pragmatic way, regard-
less of qPCR result. The first analysis consisted in assess-
ing the association between maternal haemoglogin (Hb) 
level and anaemia (defined as Hb level < 11  g/dL based 
on WHO recommendations for pregnant women) dur-
ing pregnancy (in the 1st and 3rd trimester) with con-
comitant malarial infection according to women’s group. 
Mixed models were used in order to take into account the 
correlation between Hb concentrations measured in the 
same woman. The following variables were considered 
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as potential confounding factors: maternal age (cat-
egorized according to the tertiles: < 23, 23–30,  > 30 years 
old), gravidity (primi-secundigravidae vs. multigravi-
dae), pre-pregnancy body mass index (BMI), anaemia 
before conception (defined as Hb level < 12  g/dL based 
on WHO recommendations for non-pregnant women), 
maternal education level (illiterate vs. literate), socioeco-
nomic level, and ethnicity (Toffin vs. other). Pre-preg-
nancy BMI was classified into low (< 18.5 kg/m2), normal 
(18.5−24.9  kg/m2) and high (> 25  kg/m2) according to 
WHO classification. Socioeconomic level was approxi-
mated using a synthetic score combining occupation and 
ownership of assets, which was then categorized accord-
ing to the tertiles. All variables with a P value below 0.2 
in univariate analysis were included in the multivariate 
analysis. Then, the variables were eliminated step-by-
step using the backward selection procedure, leaving 
only those variables with a P-value < 0.05. Gravidity and 
trimester of pregnancy were forced in the final multivari-
ate models. The second analysis consisted in assessing 
the association between birthweight and low birthweight 
(LBW, defined as < 2500 grams in live-birth babies) with 
malaria at delivery according to women’s group. Women 
were classified according to the highest group to which 
they belonged in either peripheral or placental blood. 
Because of convergence issues, probably due to the small 
sample size, both models were only adjusted for gravidity. 
Stata version 13 for Windows (Stata Corp., College Sta-
tion, TX) was used for all statistical analyses.
Results
Study participants characteristics
A total of 942 blood specimens were used for this study 
corresponding to 327 women who consented to par-
ticipate and from whom sufficient archived whole blood 
samples were available. Primigravidae accounted for 
7.7% of the study population (Table 2). Before pregnancy, 
57.8% of women were anaemic (Hb level < 12 g/dL). Dur-
ing pregnancy, 66% of women received 2 or 3 doses of 
IPTp with SP. The proportion of women with at least 
one microscopic malaria infection during pregnancy was 
40.0% (131/327), with 22.3% (71/319), 17.3% (52/300) and 
14.3% (39/272) infected women in the 1st, 2nd and 3rd 
trimester of pregnancy, respectively. Thirty-eight percent 
and 58.5% of women were anaemic in the 1st and 3rd tri-
mester of pregnancy, respectively (see Additional file 2). 
The prevalence of low birth weight was 8.0%. Women 
included in the present study had similar characteristics 
compared to the 411 women included in the RECIPAL 
study, except for malaria in pregnancy (defined as at least 
one microscopic infection), which was marginally higher 
in women included in the present study (40% vs. 34%, 
p = 0.10).
Malaria infection rate by diagnostic test
A total of 319, 246, 183 and 194 specimens were tested 
with uRDT, cRDT and qPCR in the 1st trimester, in the 
3rd trimester, at delivery in peripheral blood and in pla-
cental blood, respectively (Fig. 1). Mean (standard devia-
tion [SD]) gestational age in the 1st and 3rd trimester was 
11.7 (3) and 33 (3.2) weeks gestation, respectively. For 
uRDT and cRDT, kappa coefficients ranged from 96% 
to 99%; both RDTs were then considered as positive if at 
least one out of four readings was positive. Agreement 
between the initial qPCR and the quality check PCR was 
92.6%. Discrepant results were probably due to a differ-
ence in the detection limit between both PCRs [18].
The overall positivity rate detected by uRDT (16.2%) 
was slightly lower than with qPCR (18.3%), but higher 
than with cRDT (11.6%) (Table  3). Irrespective of the 
diagnostic test, infection rates were consistently the high-
est in the 1st trimester of pregnancy. The overall propor-
tion of sub-microscopic infection was 16.7%, with the 
highest prevalence in the first trimester of pregnancy 
(32%). Most infections detected during pregnancy or 
in peripheral blood at delivery (88.2%, 172/195) were 
asymptomatic.
Performance of RDTs
The uRDT identified all specimens—except two—with 
positive cRDT results, plus 46 additional specimens with 
negative cRDT results (30.0%, 46/153) (Fig. 2). Of these 
46 specimens, 28 were also positive by qPCR; mean 
(95%CI) parasite density was 20.7 p/µL (10.8–39.6). Two 
specimens were cRDT positive and uRDT negative; both 
were negative by HRP2.
Table 1 Women’s classification according to qPCR, uRDT and cRDT positivity
a At delivery, women were classified according to the highest group to which they belonged in either peripheral or placental blood; NB: specimens that were uRDT 
negative/cRDT positive (n = 2) were not classified in any of the groups
Groupa qPCR uRDT cRDT Comment
1 Negative Negative Negative Reference group
2 Positive Negative Negative PCR positive infection
3 Positive or Negative Positive Negative uRDT positive infection
4 Positive or Negative Positive or Negative Positive cRDT positive infection
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The uRDT sensitivity (60.5% (52.7−67.8)) was signifi-
cantly higher than that of the cRDT (44.2% (36.6–51.9)) 
(Table 4). The difference in sensitivity between uRDT and 
cRDT was particularly high in the 1st trimester, in mul-
tigravidae and in asymptomatic women (Table  5). The 
uRDT specificity was marginally lower than the one of 
the cRDT (93.6% vs. 95.7%, respectively) (Table 4), with 
statistically significant differences for samples collected 
in the 1st trimester, in primi/secundigravidae, in mul-
tigravidae and in asymptomatic women (Table  5). The 
positive predictive value was slightly lower for uRDT as 
compared to cRDT (68.0% vs. 69.7%), but uRDT had a 
higher negative predictive value (91.4% vs. 88.5%). Finally, 
positive and negative likelihood ratios were similar 
between uRDT and cRDT (Table 4).
Parasite density and HRP2 concentration
Among the 941 specimens with HRP2 data as well as 
concomitant RDTs and qPCR results, the geometric 
mean (95%CI) HRP2 concentration in positive specimens 
(238/941) was 2139 (1486–3079) pg/mL. Forty specimens 
were qPCR positive but negative for HRP2 (Table  6); 
all of them tested negative by both RDTs and had low 
parasite densities (geometric mean (95%CI): 18.6 p/µL 
(7.3–47.5)). A total of 106 specimens were qPCR negative 
but positive for HRP2; the concentration of HRP2 was 
higher when both RDTs were positive. Among the HRP2 
positive samples, the proportion of HRP2 positive/qPCR 
negative samples was higher in the 3rd trimester (44% 
(22/50)) and at delivery (58% (22/38) in maternal periph-
eral blood and 85% (35/41) in placental blood) than in 
the first trimester (24% (27/111)). Among the 5 women 
at delivery who were qPCR negative in peripheral blood, 
but positive by uRDT and had detectable levels of HRP2 
(in peripheral blood), all of them were negative by qPCR 
in placental blood. Figure  3 presents the distribution of 
specimens, and their positivity regarding uRDT and 
cRDT, according to parasite density and HRP2 concen-
tration. The proportion of infections that were detected 
by uRDT but not by cRDT increased with decreases in 
HRP2 levels. However, at very low concentrations of the 
antigen, both the uRDT and cRDT tended to be negative. 
The same trend was observed with decreasing parasite 
densities.
Clinical impact of uRDT‑detected malaria infections
Poor maternal and birth outcomes were more likely in 
women with uRDT-detected infections (see Additional 
file 2). In multivariate analysis, women with uRDT infec-
tions had a 3.4-times increased risk of anaemia during 
pregnancy than uninfected women (aOR (95%CI) = 3.44 
(1.29–9.19), p = 0.01) (Table  7). This excess risk was 
higher than the one associated with cRDT infections 
(aOR (95%CI) = 2.03 (1.01–4.01), p = 0.05), but the differ-
ence was not statistically significant (p = 0.64). There was 
no association between qPCR positive and RDT negative 
infections and maternal anaemia. Similar results were 
found with maternal Hb level considered as a continuous 
variable (see Additional file 3).
Table 2 General characteristics of  the  327 pregnant 
women included in the uRDT study
a Socioeconomic level was approximated using a synthetic score combining 
occupation and ownership of assets, which was then categorized according to 
the tertiles within the whole RECIPAL cohort
b Defined as a Hb level < 12 g/dL according to WHO recommendations for non-
pregnant women
General characteristics Proportion or mean (SD)
Age (years)
 Mean (SD) 26.7 (5)
 < 23 61 (18.8)
 23–30 248 (76.3)








 Low (1st tertile) 111 (34.2)
 Medium (2nd tertile) 134 (41.2)





HIV infection (n = 309) 1.7%
BMI (kg/m2)—WHO categories
 < 8, 5 9.3%
 18, 5–24 66.7%
≥ 25 24.0%
Anaemia before  conceptionb 57.8%
During pregnancy





At least one microscopic malaria infection
 During pregnancy 40.0%
 1st trimester 22.3% (71/319)
 2nd trimester 17.3% (52/300)
 3rd trimester 14.3% (39/272)
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Fig. 1 Flow diagram of included women and available specimens tested by uRDT, cRDT, qPCR and qSA for HRP2 concentration. RECIPAL study 
(Benin, 2014–2017)
Table 3 Plasmodium falciparum positivity rate by  diagnostic test in  blood samples collected during  pregnancy 
and at delivery. RECIPAL study, 2014–2017
a Mean (SD) gestational age (weeks of gestation): 11.7 (3) wg for specimens collected in the 1st trimester, 33 (3.2) wg for specimens collected in the 3rd trimester
b qPCR positive but thick blood smear negative specimens
Total (N specimens) During pregnancy At delivery
1st  trimestera 3rd  trimestera Peripheral blood Placental blood
Positivity rates in specimens tested with uRDT, cRDT and qPCR
 cRDT 11.6% (109/942) 15.7% (50/319) 10.6% (26/246) 8.2% (15/183) 9.3% (18/194)
 uRDT 16.2% (153/942) 24.8% (79/319) 13.4% (33/246) 11.5% (21/183) 10.3% (20/194)
 qPCR 18.3% (172/942) 33.5% (107/319) 15.0% (37/246) 9.8% (18/183) 5.2% (10/194)
Positivity rates in specimens tested with both microscopy and qPCR
 Microscopy 3.7% (34/926) 5.2% (16/310) 2.1% (5/244) 2.2% (4/180) 4.7% (9/192)
 Sub‑microscopic 
 infectionb
16.7% (149/992) 32.0% (94/294) 13.8% (33239) 8.0% (14/176) 4.4% (8/183)
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Women with uRDT infection at delivery had children 
with a higher risk of LBW (adjusted OR (95%CI) = 5.27 
(0.46–57.14), p = 0.17) compared with uninfected 
women, but this association did not reach statistical 
significance (Table  7). A similar result was found when 
birthweight was considered as a continuous variable (see 
Additional file 3).
Discussion
For the first time, the performance of a malaria RDT 
with a significantly improved analytical sensitivity 
as compared to commonly used RDTs [19–21] was 
evaluated in pregnant women living in a high malaria 
transmission area. Using qPCR as the reference 
standard, this uRDT had a significantly better sensitiv-
ity (60.5% (52.7−67.8)) than the studied cRDT (44.2% 
(36.6−51.9)). uRDT specificity was slightly lower 
(93.6% (91.7–95.3)) than for cRDT (95.7% (94.0–97.0)). 
The gain in sensitivity was particularly high and sta-
tistically significant in the 1st trimester of pregnancy, 
in multigravidae and in asymptomatic women (range, 
29%–33%). In addition, our results indicate that infec-
tions which can be detected by uRDT but not by cRDT, 
were associated with maternal anaemia, suggesting that 
the use of more sensitive malaria RDT in the context of 
pregnancy might provide clinical benefits for the preg-
nant women, even in a context where IPTp-SP is made 
available.
Fig. 2 Venn diagram of Plasmodium falciparum positivity by uRDT, cRDT and qPCR. RECIPAL study (Benin, 2014–2017)
Table 4 Performance of uRDT and cRDT against qPCR. RECIPAL study, 2014–2017
PPV Predictive Positive Value, NPV Negative Predictive Value, LR Likelihood Ratio
a For all performance characteristics, exact binomial confidence intervals were computed
b P-value < 0.05 using McNemar test for matched pairs
PCR Value (95%CI)a
(+) (−) Total Sensitivityb Specificityb PPV NPV Positive LR Negative LR
cRDT
 (+) 76 33 109 44.2% 95.7% 69.7% 88.5% 10.3 0.6
 (−) 96 737 833 (36.6–51.9) (94.0–97.0) (60.2–78.2) (86.2–90.6) (7.1–15) (0.5–0.7)
uRDT
 (+) 104 49 153 60.5% 93.6% 68.0% 91.4% 9.5 0.4
 (−) 68 721 789 (52.7–67.8) (91.7–95.3) (60.0–75.3) (89.2–93.2) (7.1–12.8) (0.3–0.5)
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Overall, 18.3% of specimens were qPCR positive, com-
pared to 16.2% and 11.6% with uRDT and cRDT, respec-
tively. The highest positivity rates were found for samples 
collected in the first trimester of pregnancy, before IPTp 
administration. In contrast, persistence of HRP2 (with 
qPCR negative) was observed in the 3rd trimester prob-
ably due to the clearance of parasites by IPTp. At delivery, 
positivity rate by qPCR was particularly low in placental 
blood compared to peripheral blood, possibly due to pla-
cental inhibitors or a high concentration of chelex in pla-
cental blood. Also, it was low compared with positivity 
rate by RDT. It is plausible that all infections detected in 
the peripheral blood were not necessarily of the placental 
type, and the RDTs did not make the difference by cover-
ing a wider parasite biomass.
The uRDT sensitivity ranged between 40.0% and 
83.3% depending on the trimester of pregnancy, pres-
ence of symptoms and gravidity. The highest sensitiv-
ity rates were found for peripheral specimens collected 
at delivery (83.3%) and in symptomatic women (66.7%), 
but confidence intervals were large due to small sample 
sizes and low numbers of positive specimens in these 
two groups. The overall uRDT sensitivity in our study 
(60.5% (52.7–67.8)) was lower than the one reported by 
Vasquez et  al. in Colombian pregnant women (85.7% 
(70.6–93.7)) [11]. The gain in performance between the 
cRDT and the uRDT is expected to vary from settings 
to settings, depending on the proportion of the infec-
tion that fall within the added detection window of the 
more sensitive uRDT [19, 22]. In this study, the relative 
gain in sensitivity was about 1.3 fold, similarly to previ-
ously reported data in the study by Vasquez et  al. [11]. 
This improvement was particularly evident for samples 
collected in the first trimester of pregnancy. Such a high 
gain in sensitivity probably reflected the high proportion 
of sub-microscopic infections at this period.
Only 28 (41%) out of the 68 samples which were posi-
tive by qPCR but negative by uRDT had detectable levels 
of HRP2. However, the HRP2 concentrations were very 
low, explaining the negative uRDT result. Compared to 
samples which were negative both by cRDT and uRDT, 
higher HRP2 levels were detected in samples which were 
positive by uRDT but not by cRDT (5.5-fold increase), 
and positive by both RDTs (146-fold increase). HRP2 
was detected in 48 of the 49 samples that were positive 
by uRDT but negative by qPCR. The discordance in the 
40 samples which were HRP2 negative and qPCR positive 
could be due to the presence of gametocytes or pfhrp2 
deletions, which could not be investigated [23]. The 
presence of HRP2 in qPCR negative samples could be 
explained either by infections below the qPCR detection 
limit or by the persistence of the antigen from a recently 
cleared infection [23]. Indeed, as suggested by the obser-
vation that all (n = 5) the women at delivery who were 
qPCR negative in peripheral blood but positive by uRDT 
and had detectable levels of HRP2, were also negative by 
qPCR in placental blood. In regards to qPCR detection 
limit, uRDT and cRDT sensitivity might have been lower 
by using an ultrasensitive PCR as gold standard, with 
probably a higher gain in sensitivity for uRDT compared 
to cRDT.
Women infected with malaria detected only by uRDT 
and not by cRDT, were at higher risk of anaemia com-
pared to uninfected women, highlighting the clinical 
relevance of detecting low density malaria infections 
in pregnancy. The systematic treatment of microscopic 
infections during RECIPAL study may have reduced the 
overall effect of cRDT infections on Hb level. Also, the 
analysis suggested that uRDT infections at delivery were 
associated with a five times higher risk of LBW, but this 
association was not statistically significant. Because of 
the small numbers of LBW babies and women infected 
with malaria at delivery, the analysis was probably 
Table 5 Performance of  uRDT and  cRDT against  qPCR, 
according to  the  trimester of  pregnancy, gravidity, 
and presence of fever
RECIPAL study, 2014–017
a Comparison of uRDT and cRDT performance using McNemar test for matched 
pairs. Exact binomial confidence intervals were computed
b Presence of fever (axillary temperature ≥ 37.5 °C) or history of fever in the 
preceding 24 h, whether or not infected with malaria
URDT CRDT P‑valuea
Sensitivity (95% CI)
 1st trimester 57.0% (47.1–66.5) 38.3% (29.1–48.2) < 10−3
 3rd trimester 64.9% (47.5–79.8) 54.1% (36.9–70.5) 0.05
 Delivery (peripheral 
blood)
83.3% (58.6–96.4) 61.1% (35.7–82.7) 0.05
 Delivery (placental 
blood)
40.0% (12.2 –73.8) 40.0% (12.2–73.8) –
 Primi and Secundi‑
gravidae
56.5% (41.1–71.1) 43.5% (28.9–58.9) 0.01
 Multigravidae (3 +) 63.6% (54.2–72.2) 44.9% (35.7–54.3) < 10−3
 Asymptomatic 60.8% (52.3–68.9) 43.4% (35.1–51.9) < 10−3
 Symptomatic* 66.7% (41.0 –86.7) 50.0% (26.0–74.0) 0.08
Specificity (95% CI)
 1st trimester 91.5% (86.9–94.9) 95.7% (92.1 –98.0) 0.003
 3rd trimester 95.7% (92.0–98.0) 97.1% (93.8–99.0) 0.08
 Delivery (peripheral 
blood)
96.4% (92.2–98.7) 97.6%(94.0–99.3) 0.16
 Delivery (placental 
blood)
91.3% (86.3–94.9) 92.4% (87.6–95.8) 0.41
 Primi and Secundi‑
gravidae
93.9% (88.4–97.3) 97.0% (92.4–99.2) 0.05
 Multigravidae (3 +) 94.5% (92.1–96.3) 96.3% (94.3–97.8) 0.007
 Asymptomatic 94.6% (92.3–96.4) 97.1% (95.3–98.4) < 10−3
 Symptomaticb 92.2% (82.7–97.4) 93.7% (84.8–98.3) 0.32
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underpowered to detect any significant association. In 
any case, this result has to be taken with caution for the 
two following reasons. First, malaria at delivery was the 
main exposure, which may not reflect malaria history 
during pregnancy because of a high IPTp coverage and 
the systematic treatment of microscopic infections in 
RECIPAL study. Second, one cannot exclude that women 
with a positive uRDT infection at delivery had a cRDT 
positive infection during pregnancy.
a
b
Fig. 3 Distribution of specimens by parasite density (a) and HRP2 concentration (b), according to Das et al. [19]. a The outer clear bars represent 
the specimens that were positive by qPCR only; the gray bars are the number of specimens positive by uRDT and the black bars are the number of 
specimens positive by cRDT. b The outer clear bars represent the specimens that were positive by quantitative HRP2 assay, but not by RDTs; the gray 
bars are the number of specimens positive by uRDT and the black bars are the number of specimens positive by cRDT
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Conclusion
In conclusion, these results are complementary to those 
previously reported in a low malaria transmission area. 
They confirm the higher overall performance of uRDT, 
compared to the studied conventional RDT, to detect P. 
falciparum infections in pregnant women. Indeed, the 
gain in sensitivity associated with uRDT exceeded its loss 
in specificity, with undetected infections possibly associ-
ated with poor pregnancy outcomes. The higher detec-
tion of infections using uRDT compared to cRDT was 
particularly evident in the first trimester of pregnancy, 
when sub-microscopic infections are the most prevalent. 
Since IPTp-SP is recommended from the 2nd trimes-
ter onwards, using uRDT for identifying those women 
who are infected with malaria in the first trimester of 
pregnancy may be especially relevant. Although uRDT 
will still miss almost 50% of the infected women at this 
period, women detected as infected with malaria using 
uRDT may be the ones at risk of poor outcomes. Over-
all, these encouraging results call for further prospective 
studies assessing uRDT performance and clinical rele-
vance under field conditions.
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